Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Paraneoplastic neurological and hematological syndromes associated with prostate cancer.
Gakiya M, Naka H, Saito S.
Int J Urol. 2012 May;19(5):471-4. doi: 10.1111/j.1442-2042.2011.02949.x. Epub 2012 Jan 6.
Related citations
High-intensity focused ultrasound therapy for prostate cancer.
Uchida T, Nakano M, Hongo S, Shoji S, Nagata Y, Satoh T, Baba S, Usui Y, Terachi T.
Int J Urol. 2012 Mar;19(3):187-201. doi: 10.1111/j.1442-2042.2011.02936.x. Epub 2011 Dec 21.
Editorial Comment to Population screening for prostate cancer: an overview of available studies and meta-analysis.
Hinotsu S.
Int J Urol. 2012 Feb;19(2):108-9. doi: 10.1111/j.1442-2042.2011.02925.x. Epub 2011 Dec 14. No abstract available.
Editorial Comment to Cruciferous vegetables intake and risk of prostate cancer: a meta-analysis.
Hori S.
Int J Urol. 2012 Feb;19(2):141-2. doi: 10.1111/j.1442-2042.2011.02929.x. Epub 2011 Dec 6. No abstract available.
Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA.
Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, Kanayama HO, Mikami K, Homma Y.
Int J Urol. 2011 Dec;18(12):876-81. doi: 10.1111/j.1442-2042.2011.02895.x. Erratum in: Int J Urol. 2012 Jan;19(1):94.
Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N, Suzuki H, Endo T, Takano M, Yano M, Naoi M, Nishimi D, Kawamura K, Imamoto T, Ichikawa T.
Int J Urol. 2012 Feb;19(2):169-73. doi: 10.1111/j.1442-2042.2011.02914.x. Epub 2011 Nov 29.
Cruciferous vegetables intake and risk of prostate cancer: a meta-analysis.
Liu B, Mao Q, Cao M, Xie L.
Int J Urol. 2012 Feb;19(2):134-41. doi: 10.1111/j.1442-2042.2011.02906.x. Epub 2011 Nov 28.
Population screening for prostate cancer: an overview of available studies and meta-analysis.
Lumen N, Fonteyne V, De Meerleert G, Ost P, Villeirs G, Mottrie A, De Visschere P, De Troyer B, Oosterlinck W.
Int J Urol. 2012 Feb;19(2):100-8. doi: 10.1111/j.1442-2042.2011.02912.x. Epub 2011 Nov 22.
Combined histoarchitectural and cytological biopsy grading improves grading accuracy in low-grade prostate cancer.
Helpap B, Köllermann J.
Int J Urol. 2012 Feb;19(2):126-33. doi: 10.1111/j.1442-2042.2011.02902.x. Epub 2011 Nov 22.
Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany.
Schiffer E, Bick C, Grizelj B, Pietzker S, Schöfer W.
Int J Urol. 2012 Feb;19(2):118-25. doi: 10.1111/j.1442-2042.2011.02901.x. Epub 2011 Nov 22.
Editorial Comment to Active surveillance criteria for prostate cancer: can they be applied to Japanese patients?
Suzuki M.
Int J Urol. 2012 Feb;19(2):167-8. doi: 10.1111/j.1442-2042.2011.02910.x. Epub 2011 Nov 17. No abstract available.
Editorial comment to inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells.
Huffman DM.
Int J Urol. 2012 Jan;19(1):79-80. doi: 10.1111/j.1442-2042.2011.02915.x. Epub 2011 Nov 15. No abstract available.
Active surveillance criteria for prostate cancer: can they be applied to Japanese patients?
Goto Y, Nozumi K, Miyazaki K, Matsumoto A, Inoue A, Kito H, Hasegawa N, Nagata M, Kakuta Y, Suzuki H, Yamaguchi K.
Int J Urol. 2012 Feb;19(2):163-6. doi: 10.1111/j.1442-2042.2011.02900.x. Epub 2011 Nov 9.
Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells.
Nakane K, Fujita Y, Terazawa R, Atsumi Y, Kato T, Nozawa Y, Deguchi T, Ito M.
Int J Urol. 2012 Jan;19(1):71-9. doi: 10.1111/j.1442-2042.2011.02888.x. Epub 2011 Nov 3.
Use of a combination of variables along with the PCA3 assay in better defining the "low risk" patient: a message from Pretoria to Kyoto.
Adam A.
Int J Urol. 2011 Oct;18(10):736; author reply 737. doi: 10.1111/j.1442-2042.2011.02827.x. Epub 2011 Aug 4. No abstract available.
Editorial Comment to Risk factors for pelvic lymphoceles post-radical prostatectomy.
Capitanio U, Suardi N, Montorsi F, Briganti A.
Int J Urol. 2011 Sep;18(9):644-5. doi: 10.1111/j.1442-2042.2011.02807.x. No abstract available.
Risk factors for pelvic lymphoceles post-radical prostatectomy.
Khoder WY, Trottmann M, Buchner A, Stuber A, Hoffmann S, Stief CG, Becker AJ.
Int J Urol. 2011 Sep;18(9):638-43. doi: 10.1111/j.1442-2042.2011.02797.x. Epub 2011 Jun 20.
Photodynamic diagnosis of positive margin during radical prostatectomy: preliminary experience with 5-aminolevulinic acid.
Fukuhara H, Inoue K, Satake H, Tamura K, Karashima T, Yamasaki I, Tatsuo I, Kurabayashi A, Furihata M, Shuin T.
Int J Urol. 2011 Aug;18(8):585-91. doi: 10.1111/j.1442-2042.2011.02789.x. Epub 2011 Jun 9.
Prostate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imaging.
Nishida S, Kinoshita H, Mishima T, Kurokawa H, Sakaida N, Matsuda T.
Int J Urol. 2011 Sep;18(9):653-8. doi: 10.1111/j.1442-2042.2011.02814.x. Epub 2011 Jul 26.
Editorial Comment to Health-related quality of life after salvage high-intensity focused ultrasound (HIFU) treatment for locally radiorecurrent prostate cancer.
Uchida T.
Int J Urol. 2011 Sep;18(9):651-2. doi: 10.1111/j.1442-2042.2011.02819.x. Epub 2011 Jul 20. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on